

Fig. 1 Combination effect of imatinib (Im) and docetaxel (Do) on cell proliferation.

*: $p < 0.05$. Error bars represent deviations from triplicate assays.




Fig. 2(a) Percentage of total apoptotic cells measured after 24 and 48 hrs in the absence and presence of drug; imatinib 13.5 μ M; docetaxel 14.9 nM. Im & Doc: imatinib and docetaxel. * : $P < 5E-3$. Error bars represent deviations from triplicate assays.




Fig. 2(b) Percentage cell viability after 24 and 48 hrs in the absence and presence of drug; imatinib 13.5 μ M; docetaxel 14.9 nM. Im & Doc: imatinib and docetaxel. * : $P < 5E-3$. Error bars represent deviations from triplicate assays.




Fig. 3 Invasion activity of four cell lines and NHAs in the absence of drug; UPHHJA (○), IPSB-18 (□), CLOM002 (▲), SNB-19 (×), NHA (---◆---). Error bars represent deviations from triplicate assays. NHAs were tested in duplicate in one experiment.




Fig. 4 Percentage invasion distance on day 12 (*day 11) in the absence (control) and presence of imatinib 13.5 μM and docetaxel 14.9 nM alone and in combination. Error bars represent deviations from triplicate assays.




Fig. 5 CLOM002 cell invasion on day 24 in the absence (a) and presence of the combination of imatinib 13.5 μ M and docetaxel 14.9 nM (b).




Fig. 6 Western blot analysis of tyrosine kinases PDGFR-β, PDGFR-α, Bcr-Abl, and C-Abl, multidrug resistance pumps BCRP, Pgp and the astrocyte marker GFAP. CLOM002 (1), UPHHJA (2), SNB-19 (3) IPSB-18 (4).




Fig. 7 Western blot analysis with an additional Bcr-Abl antibody. Positive control (1), SNB-19 (2), IPSB-18 (3).




Fig. 8 percentage of average invasion over 13 days with normal human astrocytes with imatinib (Imt) 40.7 μ M and docetaxel (Doc) 29 nM in comparison to the control (Ctr). Error bars represent a duplicate of one experiment.

Table 1: IC₅₀ values for imatinib and docetaxel on cell proliferation of four glioma cell lines

Drug	CLOM002	UPHHJA	IPSB-18	SNB-19	NHA
Imatinib μ M	15.7 \pm 1.3	17.7 \pm 1.3	17.4 \pm 2	18.7 \pm 2	17 \pm 0.2
Docetaxel nM	11.8 \pm 0.6	19.8 \pm 2.5	8.2 \pm 0.7	0.7 \pm 0.02	>124

Standard deviations are on triplicate assays

Table 2 Docetaxel and imatinib concentrations used in the proliferation assays in Fig. 1.

Cell line	Docetaxel (nM)	Imatinib (μ M)
CLOM002	0.5, 0.9, 1.2	3.4
UPHHJA	1.2, 2.5, 3.7	3.4
SNB-19	0.1, 0.2, 0.3	1.7
IPSB-18	1.2, 2.5, 3.7	3.4